BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Announces Pricing of Upsized $115.0 Million Public Offering GlobeNewswire January 22, 2026 EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten […]